

CC polypeptide and polynucleotides may be used in the prevention, diagnosis  
CC and treatment of diseases associated with inappropriate hTP expression.  
CC The present sequence represents the human transporter protein of the  
CC invention.  
XX  
XX  
SQ Sequence 465 AA;  
Query Match 100.0%; Score 2485; DB 23; Length 465;  
Best Local Similarity 100.0%; Pred. No. 2.4e-235;  
Matches 465; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MGPKAFSPFLLRSQSGVRLVFLLLTLHLGNCVKADDEDEDLTYNKTVLAPKIH 60  
Db 1 MGPKAFSPFLLRSQSGVRLVFLLLTLHLGNCVKADDEDEDLTYNKTVLAPKIH 60  
Qy 61 EGDITQILNSLLQGYDNKLRPDIGVRPTVETDVVNSIGPVPINNEYTIDIFAQTFW 120  
Db 61 EGDITQILNSLLQGYDNKLRPDIGVRPTVETDVVNSIGPVPINNEYTIDIFAQTFW 120  
Qy 121 DSRKFNSTMKVLMNSNMVGIWIPOTFFRNSRKSDAHWITTPNRLINWGRVLYTL 180  
Db 121 DSRKFNSTMKVLMNSNMVGIWIPOTFFRNSRKSDAHWITTPNRLINWGRVLYTL 180  
Qy 181 RLTIINAEYQLQHLNFPMDHSCPLFESSYGYPRNEIEYKWKPSVEVADPKYRLYQFAP 240  
Db 181 RLTIINAEYQLQHLNFPMDHSCPLFESSYGYPRNEIEYKWKPSVEVADPKYRLYQFAP 240  
Qy 241 VGLRNSTETHTISGDIYVIMTIFDLSRRMGYFTIOTYIPCIILTVLSWVFWINKDAVP 300  
Db 241 VGLRNSTETHTISGDIYVIMTIFDLSRRMGYFTIOTYIPCIILTVLSWVFWINKDAVP 300  
Qy 301 ARTSLGTTVLTMTLSTIARKSLPKVSYTANDLFSVCFIVFAALMEYGTLYFTSN 360  
Db 301 ARTSLGTTVLTMTLSTIARKSLPKVSYTANDLFSVCFIVFAALMEYGTLYFTSN 360  
Qy 361 OKGKTATKORKLNKASMTPLHSGSTLIPMNNISVPQEDDYSYQCLEGKDCASFCCFE 420  
Db 361 OKGKTATKORKLNKASMTPLHSGSTLIPMNNISVPQEDDYSYQCLEGKDCASFCCFE 420  
Qy 421 DCRGTSWREGRIHRIARIKIDSYSRIFFTAFALNLYVWGYLYL 465  
Db 421 DCRGTSWREGRIHRIARIKIDSYSRIFFTAFALNLYVWGYLYL 465

RESULT 2  
ID ABB08234 standard; Protein: 465 AA.  
XX  
AC ABB08234;  
XX  
DT 18-JUN-2002 (first entry)  
XX  
DE Human gamma-amino butyric acid (GABA) receptor subunit #1.  
XX  
KW Human; GABA; gamma aminobutyric acid; receptor; gene therapy; protein.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT Misc-difference 257 /note- "Encoded by TAK"  
XX  
PN WO200200720-A2.  
XX  
PD 03-JAN-2002.  
XX  
PF 27-JUN-2001; 2001WO-US20417.  
XX  
PR 27-JUN-2000; 2000US-214083P.  
XX  
PA (LEX1-) LEXICON GENETICS INC.  
XX  
PI Walke DW, Friddle CJ, Mathur B, Turner CA;

XX WPI; 2002-139905/18.  
DR N-PSDB; ABA96143, ABA96145.  
XX  
XX New polynucleotides encoding novel human proteins sharing sequence  
PT similarity with membrane receptors e.g. gamma aminobutyric acid  
PT receptors, for generating primers and probes used to identify drug  
PT targets.  
XX  
XX Claim 1: Page 35-37; 38pp; English.  
XX  
XX The sequence represents a novel human polypeptide having sequence  
CC similarity with gamma aminobutyric acid (GABA) receptors. The invention  
CC relates to novel human protein (NRP) encoding sequence, where the protein  
CC is a human gamma aminobutyric acid receptor. The sequence may have a use  
CC in gene therapy. The NRP polynucleotide sequences that encode NRP  
CC subunits, when knocked out provide a method for:  
CC (i) identifying phenotypic expression of the particular gene as well as  
CC assigning function to previously unknown genes,  
CC (ii) identifying a coding sequence and mapping a unique gene to a  
CC particular chromosome; and  
CC (iii) identifying biologically relevant splice junctions.  
CC The NRP polynucleotide sequences are useful:  
CC (i) in gene therapy techniques for the modulation of NRP expression;  
CC (ii) for detecting mutant NRPs or inappropriately expressed NRPs for  
CC the diagnosis of disease;  
CC (iii) for screening drugs effective in treatment of symptomatic or  
CC phenotypic manifestations of perturbing the normal function of NRP in  
CC the body.  
CC The sequences are also useful for identifying mutations associated with a  
CC particular disease and also as a prognostic or diagnostic assay. The  
CC nucleic acid molecule is also useful in the molecular mutagenesis/  
CC evolution of proteins that are at least partially encoded by the  
CC described new sequences.  
XX  
XX Sequence 465 AA;

Query Match 100.0%; Score 2485; DB 23; Length 465;  
Best Local Similarity 100.0%; Pred. No. 2.4e-235;  
Matches 465; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MGPKAFSPFLLRSQSGVRLVFLLLTLHLGNCVKADDEDEDLTYNKTVLAPKIH 60  
Db 1 MGPKAFSPFLLRSQSGVRLVFLLLTLHLGNCVKADDEDEDLTYNKTVLAPKIH 60  
Qy 61 EGDITQILNSLLQGYDNKLRPDIGVRPTVETDVVNSIGPVPINNEYTIDIFAQTFW 120  
Db 61 EGDITQILNSLLQGYDNKLRPDIGVRPTVETDVVNSIGPVPINNEYTIDIFAQTFW 120  
Qy 121 DSRKFNSTMKVLMNSNMVGIWIPOTFFRNSRKSDAHWITTPNRLINWGRVLYTL 180  
Db 121 DSRKFNSTMKVLMNSNMVGIWIPOTFFRNSRKSDAHWITTPNRLINWGRVLYTL 180  
Qy 181 RLTIINAEYQLQHLNFPMDHSCPLFESSYGYPRNEIEYKWKPSVEVADPKYRLYQFAP 240  
Db 181 RLTIINAEYQLQHLNFPMDHSCPLFESSYGYPRNEIEYKWKPSVEVADPKYRLYQFAP 240  
Qy 241 VGLRNSTETHTISGDIYVIMTIFDLSRRMGYFTIOTYIPCIILTVLSWVFWINKDAVP 300  
Db 241 VGLRNSTETHTISGDIYVIMTIFDLSRRMGYFTIOTYIPCIILTVLSWVFWINKDAVP 300  
Qy 301 ARTSLGTTVLTMTLSTIARKSLPKVSYTANDLFSVCFIVFAALMEYGTLYFTSN 360  
Db 301 ARTSLGTTVLTMTLSTIARKSLPKVSYTANDLFSVCFIVFAALMEYGTLYFTSN 360  
Qy 361 OKGKTATKORKLNKASMTPLHSGSTLIPMNNISVPQEDDYSYQCLEGKDCASFCCFE 420  
Db 361 OKGKTATKORKLNKASMTPLHSGSTLIPMNNISVPQEDDYSYQCLEGKDCASFCCFE 420  
Qy 421 DCRGTSWREGRIHRIARIKIDSYSRIFFTAFALNLYVWGYLYL 465  
Db 421 DCRGTSWREGRIHRIARIKIDSYSRIFFTAFALNLYVWGYLYL 465